Alzai Health and Quanterix Sign MOU to Combine AI Risk Identification With Blood Biomarkers

Alzai Health Corp. signed a memorandum of understanding with Quanterix Corporation on November 13, 2026, to explore collaboration on improving early detection and assessment of Alzheimer's disease. The Toronto-based health technology company announced the non-binding agreement, Aktien reported. The companies will assess combining Alzai's AI-driven risk identification technology with Quanterix's blood-based LucentAD biomarkers.

How the Alzai and Quanterix Collaboration Would Work

Under the memorandum, Alzai Health and Quanterix plan to examine ways to pair Alzai's AI technology for identifying Alzheimer's risk with Quanterix's LucentAD blood biomarkers. The stated aim is a holistic approach to identifying and assessing people at elevated risk of Alzheimer's. The companies intend to work with healthcare providers, health systems and other healthcare organizations to explore earlier patient identification, more targeted diagnostics and better clinical decision-making.

"This collaboration is an important step in ALZAI's strategic efforts to expand the reach and potential applications of our AI-driven technology for identifying disease risk," said Hayim Raclaw, CEO of Alzai Health Corp. "Quanterix is a well-established innovator in biomarker detection and Alzheimer's diagnostics." Raclaw said combining the companies' complementary capabilities has the potential to enable a more efficient approach to identifying people at elevated Alzheimer's risk and directing them to appropriate diagnostics.

Quanterix is restructuring its sales organization into dedicated teams for spatial biology, Simoa products and clinical-trial services, Yahoo reported in August 2026, citing burdensome combined-sales models and market pressures.

Alzai's Platform Scale Behind the Agreement

Alzai's platform has processed more than 500,000 patients, according to akta.pro company records. Validation was performed on real-world longitudinal healthcare data covering more than 1.1 million U.S. patients, with approximately 38 million blood chemistry lab test results and over 3 million chronic disease diagnostic records representing over 100 million clinical data points. In July 2026, Alzai signed a strategic teaming agreement with Centauri Health Solutions for U.S. commercialization, gaining access to Centauri's 60 million member base and national relationships with providers and health plans in Medicare Advantage and value-based care settings.

Alzai's Path to the Quanterix Agreement

Alzai joined the Alzheimer's Association Business Consortium in November 2026 to expand its engagement in Alzheimer's research, Stock Titan reported. In July 2026, the company announced validation of its AI-driven Alzheimer's risk screening solution using large-scale U.S. patient data, FinancialContent Business Page reported. Alzai also signed a strategic teaming agreement with Centauri Health Solutions in July 2026 to collaboratively market AI-driven risk stratification technology for identifying patients at high risk for early-stage undiagnosed Alzheimer's Disease in the U.S., FinancialContent Business Page reported.

Quanterix's Pending FDA Decision

Quanterix is targeting a fourth-quarter FDA decision for its Alzheimer's blood test, Yahoo reported in August 2026.